Supriya Lifescience Ltd (NSE:SUPRIYA)

Q3 2026 Supriya Lifescience Ltd Earnings Call Transcript

Feb 9, 2026 / 05:30 AM GMT

Release Date Price: ₹686.95 (-0.14%)

Transcript

Key Points

Positve

Supriya Lifescience Ltd (BOM:543434) reported a revenue growth of 11% year-on-year for Q3 FY26, driven by robust demand across its product portfolio.
The company achieved a strong EBITDA margin of 34.9% and a PAT margin of 24.1%, reflecting efficient operational execution.
Exports remain a key growth driver, contributing 82% of total revenues, with significant growth in the LATAM region.
The company successfully launched a key cardiovascular product and an ADHD product, with expectations for meaningful contributions in the coming quarters.
Supriya Lifescience Ltd (BOM:543434) is on track to achieve its guidance of approximately 20% annual revenue growth and aims to reach the INR 1,000 crore revenue milestone by FY27.

Negative

The company faced a slowdown in Q3 due to holiday-related shipment delays, impacting revenue recognition.
There is a dependency on regulatory approvals for new products, which could affect the timeline for realizing potential revenue growth.
The company has not yet secured firm annual contracts for its ATS 8 product, which could pose a risk to projected sales volumes.
The EU CGMP inspection at the Ambernath facility has been delayed due to manpower issues, potentially affecting regulatory approval timelines.
The CDMO segment is still in the early stages of development, with no significant contracts secured yet, which may delay expected revenue contributions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SPRL.NS - Supriya Lifescience Ltd
Q3 2026 Supriya Lifescience Ltd Earnings Call
Feb 10, 2026 / 05:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Supriya Life Science Limited Q3 FY26 earnings call.

As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing, then 0 on your touchtone phone. Please note that this conference is being recorded. Anna, hand the conference over to Ms. Neha Salian for her opening remarks.

Thank you and over to you, ma'am.

Thank you, Ira.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.